Geode Capital Management’s Eledon Pharmaceuticals ELDN Stock Holding History

Geode Capital Management’s Portfolio ELDN Stock Details ELDN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.71M	Buy	1,956,601 +164,818	+9%	+$599K	﹤0.01%	2683
2026 Q1	$5.52M	Buy	1,791,783 +370,166	+26%	+$872K	﹤0.01%	2688
2025 Q4	$2.15M	Buy	1,421,617 +52,677	+4%	+$125K	﹤0.01%	3142
2025 Q3	$3.55M	Sell	1,368,940 -15,000	-1%	-$43.9K	﹤0.01%	2948
2025 Q2	$3.75M	Buy	1,383,940 +717,223	+108%	+$2.15M	﹤0.01%	2878
2025 Q1	$2.26M	Buy	666,717 +3,616	+0.5%	+$14.9K	﹤0.01%	2993
2024 Q4	$2.73M	Buy	663,101 +285,043	+75%	+$1.12M	﹤0.01%	3023
2024 Q3	$942K	Buy	378,058 +33,569	+10%	+$89.9K	﹤0.01%	3372
2024 Q2	$910K	Buy	344,489 +163,588	+90%	+$390K	﹤0.01%	3341
2024 Q1	$373K	Buy	180,901 +4,862	+3%	+$8.68K	﹤0.01%	3716
2023 Q4	$317K	Hold	176,039	–	–	﹤0.01%	3777
2023 Q3	$241K	Buy	176,039 +6,389	+4%	+$8.53K	﹤0.01%	3909
2023 Q2	$232K	Buy	169,650 +40,499	+31%	+$84.4K	﹤0.01%	3980
2023 Q1	$305K	Hold	129,151	–	–	﹤0.01%	3854
2022 Q4	$299K	Sell	129,151 -314	-0.2%	-$776	﹤0.01%	3888
2022 Q3	$357K	Buy	129,465 +679	+0.5%	+$2.16K	﹤0.01%	3906
2022 Q2	$314K	Buy	128,786 +2,076	+2%	+$6.33K	﹤0.01%	4008
2022 Q1	$499K	Hold	126,710	–	–	﹤0.01%	3931
2021 Q4	$558K	Sell	126,710 -848	-0.7%	-$4.29K	﹤0.01%	3986
2021 Q3	$788K	Buy	127,558 +2,944	+2%	+$20.6K	﹤0.01%	3811
2021 Q2	$985K	Buy	124,614 +25,491	+26%	+$240K	﹤0.01%	3610
2021 Q1	$1.06M	Buy	+99,123	New	+$1.5M	﹤0.01%	3530
2020 Q4	–	Sell	-710	Closed	-$12K	–	4275
2020 Q3	$12K	Hold	710	–	–	﹤0.01%	4143
2020 Q2	$5K	Hold	710	–	–	﹤0.01%	4100
2020 Q1	$4K	Hold	710	–	–	﹤0.01%	4106
2019 Q4	$7K	Hold	710	–	–	﹤0.01%	4201
2019 Q3	$8K	Hold	710	–	–	﹤0.01%	4180
2019 Q2	$12K	Buy	710 +59	+9%	+$2.58K	﹤0.01%	4183
2019 Q1	$47K	Hold	651	–	–	﹤0.01%	4028
2018 Q4	$18K	Hold	651	–	–	﹤0.01%	4095
2018 Q3	$54K	Buy	+651	New	+$66.4K	﹤0.01%	4022
2017 Q2	–	Sell	-524	Closed	-$70K	–	4090
2017 Q1	$70K	Sell	524 -9	-2%	-$1.32K	﹤0.01%	3892
2016 Q4	$84K	Buy	533 +75	+16%	+$14.4K	﹤0.01%	3821
2016 Q3	$113K	Buy	458 +100	+28%	+$36.6K	﹤0.01%	3779
2016 Q2	$319K	Buy	358 +34	+10%	+$37.5K	﹤0.01%	3407
2016 Q1	$294	Sell	324 -1	-0.3%	-$982	﹤0.01%	3490
2015 Q4	$458K	Buy	325 +9	+3%	+$15.7K	﹤0.01%	3309
2015 Q3	$529K	Buy	316 +51	+19%	+$105K	﹤0.01%	3189
2015 Q2	$571K	Buy	265 +18	+7%	+$34.8K	﹤0.01%	3140
2015 Q1	$452K	Buy	247 +15	+6%	+$33.1K	﹤0.01%	3238
2014 Q4	$554K	Buy	+232	New	+$551K	﹤0.01%	3144

Other funds holding ELDN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return

CCM

Catalio Capital Management New York $532M AUM 166.55% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

Geode Capital Management's ELDN Position: Q2 2026 in Review

Geode Capital Management increased its Eledon Pharmaceuticals (ELDN) stake by 9.2% in Q2 2026, buying an estimated $599K and bringing the position to 1,956,601 shares worth $7.71M. The position accounts for ﹤0.01% of the portfolio, ranked #2683.

Geode Capital Management first reported a position in ELDN in Q4 2014 and has held it in 41 quarters since. 147 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

Geode Capital Management held 1,956,601 shares of Eledon Pharmaceuticals worth $7.71M as of Q2 2026.
Geode Capital Management bought 164,818 Eledon Pharmaceuticals shares in Q2 2026, an estimated $599K.
Eledon Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2683 holding.
Geode Capital Management first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 41 quarters since.
147 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.